Split DNA Tetrahedron-Mediated Spatiotemporal-Hierarchy CRISPR Cascade Integrated with Au@Pt Nanolabels and Artificial Intelligence for a Cervical Cancer MicroRNA Bioassay.

Journal: ACS nano
Published Date:

Abstract

The screening and monitoring of microRNAs as cancer molecular biomarkers is clinically significant, but traditional methods lack sufficient sensitivity, accuracy, and convenience. The CRISPR-colorimetric lateral flow assay (CLFA) integration offers a promising and efficient solution; however, cumbersome preamplification and poor quantification hinder clinical adoption. In this study, we developed a one-step isothermal CRISPR-Cas cascaded sensing system that is preamplification-free. At its core is a designed and selected split DNA tetrahedron activator, employing spatiotemporal-hierarchy mechanisms to precisely bidirectionally drive the kinetics of two Cas enzymes, accelerating the activation of Cas13a while delaying the initiation of Cas12a, to achieve optimal balance. This system enables ultrasensitive, single-step, single-tube, and rapid detection of a cervical cancer relative biomarker, microRNA-21, achieving a limit of detection of 38 aM with a broad linear range. The CRISPR system is further integrated with CLFA enhanced by ultrathin platinum-protected gold nanolabels (Au@Pt, also named Au@s-Pt), along with a smartphone equipped with dual convolutional neural network models (YOLO v5 and MobileNet v3), enabling more precise, rapid quantification of target miRNA. Using this integrated platform, miRNA-21 levels in cervical cancer and precancerous samples can be accurately quantified with approximately 30 min at low cost and without the need for large, sophisticated instruments, with results showing good concordance with quantitative real-time polymerase chain reaction. This platform provides an efficient, highly sensitive, user-friendly, and quantifiable point-of-care testing solution.

Authors

  • Xiaohui Zhan
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Yujia Jiang
    National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, China.
  • Zhiyu Li
    Department of Medical Imaging, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 201306, China.
  • Xiaoqin Hu
    National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, People's Republic of China.
  • Fang Lan
    Basic Medical College, Shanghai University of Traditional Chinese Medicine, Pudong, China.
  • Binwu Ying
    Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610064, China. zhoujuan39@wchscu.cn.
  • Yao Wu